These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38928392)

  • 21. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
    Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
    Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
    Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut Microbiota in Lung Cancer: Where Do We Stand?
    Georgiou K; Marinov B; Farooqi AA; Gazouli M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
    Bhalla S; Doroshow DB; Hirsch FR
    Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.
    Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of key microRNAs and hub genes in non-small-cell lung cancer using integrative bioinformatics and functional analyses.
    Song F; Xuan Z; Yang X; Ye X; Pan Z; Fang Q
    J Cell Biochem; 2020 Mar; 121(3):2690-2703. PubMed ID: 31692035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologic colonic uptake of
    Cvetkovic L; Régis C; Richard C; Derosa L; Leblond A; Malo J; Messaoudene M; Desilets A; Belkaid W; Elkrief A; Routy B; Juneau D
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1550-1559. PubMed ID: 33128571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
    Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
    Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.
    Derosa L; Iebba V; Silva CAC; Piccinno G; Wu G; Lordello L; Routy B; Zhao N; Thelemaque C; Birebent R; Marmorino F; Fidelle M; Messaoudene M; Thomas AM; Zalcman G; Friard S; Mazieres J; Audigier-Valette C; Sibilot DM; Goldwasser F; Scherpereel A; Pegliasco H; Ghiringhelli F; Bouchard N; Sow C; Darik I; Zoppi S; Ly P; Reni A; Daillère R; Deutsch E; Lee KA; Bolte LA; Björk JR; Weersma RK; Barlesi F; Padilha L; Finzel A; Isaksen ML; Escudier B; Albiges L; Planchard D; André F; Cremolini C; Martinez S; Besse B; Zhao L; Segata N; Wojcik J; Kroemer G; Zitvogel L
    Cell; 2024 Jun; 187(13):3373-3389.e16. PubMed ID: 38906102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
    Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
    Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
    Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
    Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
    Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
    Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
    Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
    Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
    Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
    Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
    J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.